HANGZHOU TIGERMED CONSULTING CO., LTD ETFs Hangzhou Tigermed Consulting Co., Ltd
Equities
300347
CNE100001KV8
Biotechnology & Medical Research
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.66 CNY | +2.96% |
|
+2.77% | -11.48% |
| Jul. 03 | Tranche Update on Hangzhou Tigermed Consulting Co., Ltd's Equity Buyback Plan announced on May 24, 2024. | CI |
| Jun. 18 | Hangzhou Tigermed Consulting Co., Ltd Announces Executive Changes | CI |
ETFs positioned on Hangzhou Tigermed Consulting Co., Ltd
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.98% | 1 M€ | -9.86% | - | |
| 0.69% | 1 M€ | -22.82% | - | |
| 0.18% | 35 M€ | -5.85% | - | |
| 0.02% | 2 M€ | -.--% | ||
| 0.02% | 7 M€ | -.--% | - | |
| 0.02% | 4 M€ | -11.56% | ||
| 0.01% | 114 M€ | +8.75% | - | |
| 0.00% | 451 M€ | +10.37% | - | |
| 0.00% | 2,838 M€ | +13.84% | - | |
| 0.00% | 152 M€ | +11.78% | - | |
| 0.00% | 35 M€ | +7.92% | - | |
| 0.00% | 4 M€ | -4.41% | - | |
| 0.00% | 36 M€ | +11.52% | - | |
| 0.00% | 32 M€ | +6.20% | - | |
| 0.00% | 40 M€ | +8.04% | - | |
| 0.00% | 324 M€ | +9.41% | - | |
| 0.00% | 17 M€ | +4.32% | - | |
| 0.00% | 7 M€ | +6.74% | - |
Hangzhou Tigermed Consulting Co, Ltd. specialises in providing professional services to pharmaceutical and biotech companies. The group supports its clients in all processes of clinical development and product commercialization. Net sales break down by activity as follows:
- provision of clinical trial services and related technological services (51.8%);
- provision of clinical research consulting services (48.2%).
China accounts for 46% of sales.
Calendar
2024-08-28
- Q2 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
21
Last Close Price
48.66
CNY
Average target price
74.23
CNY
Spread / Average Target
+52.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -11.48% | 5.23B | |
| +23.50% | 45.01B | |
| +47.19% | 40.96B | |
| -5.16% | 38.62B | |
| +36.37% | 32.6B | |
| -7.79% | 27.49B | |
| +18.06% | 27.17B | |
| +47.29% | 14.61B | |
| +41.91% | 12.95B | |
| -1.02% | 11.36B |
- Stock Market
- Equities
- 300347 Stock
- ETFs Hangzhou Tigermed Consulting Co., Ltd
